{
    "items": "143",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock",
            "url": "https://www.fool.com/investing/2024/04/06/eli-lillys-wegovy-competitor-is-causing-supply-con/",
            "time_published": "20240406T123000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Things are going exactly as planned for the biotech giant.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771534/physician-talking-to-patient.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.16125,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.415535",
                    "ticker_sentiment_score": "0.140382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.136348",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-pullback-weight-loss-drugs/",
            "time_published": "20240405T163500",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/SOTD-4-5-2024NVO.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.21862,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.254307",
                    "ticker_sentiment_score": "0.13511",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.187818",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.187818",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.064623",
                    "ticker_sentiment_score": "0.294962",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GMAB",
                    "relevance_score": "0.064623",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.373378",
                    "ticker_sentiment_score": "0.138725",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Understanding Eli Lilly and Co's Position In Pharmaceuticals Industry Compared To Competitors - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/news/24/04/38111799/understanding-eli-lilly-and-cos-position-in-pharmaceuticals-industry-compared-to-competitors",
            "time_published": "20240405T150016",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly and Co LLY against its key competitors in the ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.181517,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.461997",
                    "ticker_sentiment_score": "0.274107",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/04/38111253/eli-lilly-and-co-options-trading-a-deep-dive-into-market-sentiment",
            "time_published": "20240405T143133",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 22 trades. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.130804,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.821469",
                    "ticker_sentiment_score": "0.166043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "How to Create a Stock Portfolio that Pays $100 a Month",
            "url": "https://www.zacks.com/stock/news/2250736/how-to-create-a-stock-portfolio-that-pays-100-a-month",
            "time_published": "20240404T210500",
            "authors": [
                "Tracey Ryniec"
            ],
            "summary": "Forget buying a CD. Here's how to set yourself up with individual stocks that will net you passive income.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2427.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999967"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.226183,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.377142",
                    "ticker_sentiment_score": "0.132652",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VICI",
                    "relevance_score": "0.425925",
                    "ticker_sentiment_score": "0.28991",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.377142",
                    "ticker_sentiment_score": "0.408411",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.425925",
                    "ticker_sentiment_score": "0.161418",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CZR",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.16694",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BOWL",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.16694",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KEY",
                    "relevance_score": "0.326643",
                    "ticker_sentiment_score": "0.111634",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?",
            "url": "https://www.fool.com/investing/2024/04/04/could-this-1-detail-help-viking-top-lilly-novo/",
            "time_published": "20240404T085500",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Viking shares have soared recently on optimism about its program.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771655%2Fgettyimages-1351333930.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.239522,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.302808",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.104156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.054857",
                    "ticker_sentiment_score": "0.130001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.302808",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Topped the Market Today",
            "url": "https://www.fool.com/investing/2024/04/03/why-eli-lilly-stock-topped-the-market-today/",
            "time_published": "20240403T203102",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "One analyst following the company believes it could grow its revenue meaningfully this year.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771731/stethescope-atop-us-currency-and-coins.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.279871,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.549581",
                    "ticker_sentiment_score": "0.361821",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.294093",
                    "ticker_sentiment_score": "0.259711",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy - Eli Lilly and Co  ( NYSE:LLY ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/markets/equities/24/04/38077966/eli-lilly-struggles-to-keep-pace-with-mounjaro-zepbound-demand-currently-unavailable-on-amazon-p",
            "time_published": "20240403T200742",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company LLY stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-ai.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.033528,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.493442",
                    "ticker_sentiment_score": "-0.157577",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "0.083065",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "-0.18623",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Verve  ( VERV )  Pauses Enrollment in Cholesterol Study, Stock Falls",
            "url": "https://www.zacks.com/stock/news/2250054/verve-verv-pauses-enrollment-in-cholesterol-study-stock-falls",
            "time_published": "20240403T174000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.108569,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.176717",
                    "ticker_sentiment_score": "0.278914",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.290262",
                    "ticker_sentiment_score": "0.221413",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ANIP",
                    "relevance_score": "0.290262",
                    "ticker_sentiment_score": "0.201066",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.176717",
                    "ticker_sentiment_score": "0.158941",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/asia/24/04/38075244/novo-nordisks-popular-diabetes-drug-ozempic-starter-kits-face-extended-shortages-in-germany-faces-bi",
            "time_published": "20240403T173747",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic ( semaglutide ) will not be available in Germany during the second quarter.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_9.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.007237,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "-0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.340915",
                    "ticker_sentiment_score": "0.064828",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/04/38071716/unpacking-the-latest-options-trading-trends-in-eli-lilly-and-co",
            "time_published": "20240403T150119",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 41 unusual trades. Delving into the details, we found 26% of traders were bullish, while 73% showed bearish tendencies.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.065172,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.799128",
                    "ticker_sentiment_score": "0.056879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.092569",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Rally Holds Support; Five Stocks Eye Buy Points",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-holds-support-meta-near-buy-point-tesla-skid/",
            "time_published": "20240403T120900",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures: Stock Market Rally Holds Support, Meta Near Buy Point. Tesla Skids Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-bullBearFrankfurt-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                }
            ],
            "overall_sentiment_score": 0.029155,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.129795",
                    "ticker_sentiment_score": "-0.051452",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.052112",
                    "ticker_sentiment_score": "-0.085286",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.052112",
                    "ticker_sentiment_score": "-0.085286",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.180943",
                    "ticker_sentiment_score": "0.100045",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.280762",
                    "ticker_sentiment_score": "0.038775",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PVH",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "-0.089248",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.256179",
                    "ticker_sentiment_score": "-0.214866",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "-0.07445",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.089337",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIVN",
                    "relevance_score": "0.052112",
                    "ticker_sentiment_score": "0.09456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.180943",
                    "ticker_sentiment_score": "0.088684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "-0.054697",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras - Costco Wholesale  ( NASDAQ:COST ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/24/04/38063177/costco-long-known-for-rotisserie-chicken-and-hot-dogs-counters-junk-food-with-weight-loss-plan-to-he",
            "time_published": "20240403T072117",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Costco Wholesale Corporation COST has launched a weight management program to help its members in their weight loss journey. The program will provide access to popular weight loss medications from pharmaceutical giants Eli Lilly and Co LLY and Novo Nordisk A/S NVO.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/CostCo_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.233351,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.234307",
                    "ticker_sentiment_score": "0.111226",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.308891",
                    "ticker_sentiment_score": "0.165273",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.104601",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.234307",
                    "ticker_sentiment_score": "0.009183",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Ascends While Market Falls: Some Facts to Note",
            "url": "https://www.zacks.com/stock/news/2249391/eli-lilly-lly-ascends-while-market-falls-some-facts-to-note",
            "time_published": "20240402T214518",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The latest trading day saw Eli Lilly (LLY) settling at $763.96, representing a +0.45% change from its previous close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default349.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976913"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.128657,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.520477",
                    "ticker_sentiment_score": "0.185292",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Market Bends As Yields Jump; Tesla Skids As 5 Stocks Hang Tough",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-slides-tesla-skids-meta-buy-point/",
            "time_published": "20240402T205300",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures: Market Slides But Holds Key Levels. Tesla Skids As Meta Eyes Buy Point Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-bullBearFrankfurt-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.058028,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.141893",
                    "ticker_sentiment_score": "-0.053992",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.057011",
                    "ticker_sentiment_score": "-0.085698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.057011",
                    "ticker_sentiment_score": "-0.085698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.197643",
                    "ticker_sentiment_score": "0.106808",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.305921",
                    "ticker_sentiment_score": "0.032325",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PVH",
                    "relevance_score": "0.085426",
                    "ticker_sentiment_score": "-0.082956",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.252405",
                    "ticker_sentiment_score": "-0.184414",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.169875",
                    "ticker_sentiment_score": "0.09468",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIVN",
                    "relevance_score": "0.057011",
                    "ticker_sentiment_score": "0.09494",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.197643",
                    "ticker_sentiment_score": "0.094691",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.113731",
                    "ticker_sentiment_score": "-0.051179",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race - AstraZeneca  ( NASDAQ:AZN ) ",
            "url": "https://www.benzinga.com/general/biotech/24/04/38055367/astrazeneca-ceo-highlights-decade-long-sales-goal-of-45b-along-with-investor-doubts-as-it-lags-in",
            "time_published": "20240402T185401",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "AstraZeneca Plc's AZN Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a goal set a decade ago amid pressure from U.S. rival Pfizer Inc PFE.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/AstraZeneca-HQ-in-Cambridge-UK_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.214279,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "-0.093594",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "-0.111146",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.727604",
                    "ticker_sentiment_score": "0.189804",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "-0.093594",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.285526",
                    "ticker_sentiment_score": "-0.124969",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38055169/citi-monitors-competitive-threats-to-eli-lilly-says-it-is-positioned-to-maintain-le",
            "time_published": "20240402T184150",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Citi Research has increased the price target for Eli Lilly And Co LLY, reflecting increased anticipated risk-adjusted peak sales for the company's oral small molecule GLP-1 agonist orforglipron as a mono/fixed-dose combination.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.109662,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.72844",
                    "ticker_sentiment_score": "0.192565",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362505",
                    "ticker_sentiment_score": "0.194362",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.246582",
                    "ticker_sentiment_score": "0.120995",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Is Verve Therapeutics Stock Trading Lower On Tuesday? - Verve Therapeutics  ( NASDAQ:VERV ) ",
            "url": "https://www.benzinga.com/general/biotech/24/04/38052320/gene-therapy-side-effects-verve-therapeutics-halts-enrollment-of-lead-gene-therapy-trial-in-patie",
            "time_published": "20240402T161914",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Verve Therapeutics Inc VERV announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in patients with a genetic condition that leads to high cholesterol levels, which raises the risk of heart disease.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Gene-therapy-30281390100-418857d210-o_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.180933,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.356865",
                    "ticker_sentiment_score": "0.286711",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.183198",
                    "ticker_sentiment_score": "0.128895",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.271777",
                    "ticker_sentiment_score": "0.120376",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience",
            "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-navigates-weight-loss-drug-competition-with-technical-resilience-1033215940",
            "time_published": "20240402T160915",
            "authors": [
                "Surbhi Jain"
            ],
            "summary": "Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's ( NYSE:LLY ) strategic positioning and technical resilience present a compelling investment opportunity.",
            "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_1.jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99793"
                }
            ],
            "overall_sentiment_score": 0.231119,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.640349",
                    "ticker_sentiment_score": "0.379462",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.008505",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer says Microsoft's unbundling of Teams and Office is good news for this portfolio stock",
            "url": "https://www.cnbc.com/2024/04/02/jim-cramer-microsoft-teams-office-unbundling-good-news-for-salesforce.html",
            "time_published": "20240402T160800",
            "authors": [
                "Morgan Chittum"
            ],
            "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107356114-1704816779151-gettyimages-1228524873-AFP_8PZ69L.jpeg?v=1712070146&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980716"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.139618,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.247838",
                    "ticker_sentiment_score": "0.111864",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.326283",
                    "ticker_sentiment_score": "0.138622",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.166743",
                    "ticker_sentiment_score": "0.082876",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38051329/eli-lilly-stock-navigates-weight-loss-drug-competition-with-technical-resilience",
            "time_published": "20240402T153943",
            "authors": [
                "Surbhi Jain"
            ],
            "summary": "Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's LLY strategic positioning and technical resilience present a compelling investment opportunity. Zepbound boasts impressive weight-loss efficacy in ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                }
            ],
            "overall_sentiment_score": 0.281184,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.575407",
                    "ticker_sentiment_score": "0.435661",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.18046",
                    "ticker_sentiment_score": "0.012024",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ten Stocks Showing This Bullish Action, Including A Mag 7 Titan",
            "url": "https://www.investors.com/news/meta-platforms-amd-10-stocks-bullish-action/",
            "time_published": "20240402T114500",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Meta Platforms, AMD Lead 10 Stocks Showing This Bullish Action Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/stock-bounce-back-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.18806,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.153314",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.239541",
                    "ticker_sentiment_score": "0.13668",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.227132",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.103429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYBR",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.137013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NET",
                    "relevance_score": "0.239541",
                    "ticker_sentiment_score": "0.105097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.297427",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.239541",
                    "ticker_sentiment_score": "0.068878",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Apple, NVIDIA, Eli Lilly, American Tower and McKesson",
            "url": "https://www.zacks.com/stock/news/2248815/the-zacks-analyst-blog-highlights-apple-nvidia-eli-lilly-american-tower-and-mckesson",
            "time_published": "20240402T093700",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Apple, NVIDIA, Eli Lilly, American Tower and McKesson are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/429.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.23177,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMT",
                    "relevance_score": "0.16117",
                    "ticker_sentiment_score": "0.040951",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.45825",
                    "ticker_sentiment_score": "0.203377",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.31583",
                    "ticker_sentiment_score": "0.06747",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.45825",
                    "ticker_sentiment_score": "0.374601",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "MCK",
                    "relevance_score": "0.16117",
                    "ticker_sentiment_score": "0.040951",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is It Too Late to Buy Eli Lilly Stock?",
            "url": "https://www.fool.com/investing/2024/04/02/is-it-too-late-to-buy-eli-lilly-stock/",
            "time_published": "20240402T091000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "There's more to the Lilly story than just excellence in one treatment area.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771415%2Fgettyimages-613345556.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972756"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.25364,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.50287",
                    "ticker_sentiment_score": "0.312039",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.190076",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.190076",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "-0.10048",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "-0.10048",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Stock Reports for Apple, NVIDIA & Eli Lilly",
            "url": "https://www.zacks.com/research-daily/2248263/top-stock-reports-for-apple-nvidia-eli-lilly",
            "time_published": "20240401T183800",
            "authors": [
                "Sheraz Mian"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and Eli Lilly and Company (LLY).",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default59.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.239366,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.225728",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.100729",
                    "ticker_sentiment_score": "0.029195",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.387374",
                    "ticker_sentiment_score": "0.386666",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
            "url": "https://www.zacks.com/stock/news/2248231/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
            "time_published": "20240401T130014",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default313.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.235146,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.523044",
                    "ticker_sentiment_score": "0.153181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Missed the \"Magnificent Seven\"? Try Buying These 3 Forever Stocks Instead",
            "url": "https://www.fool.com/investing/2024/04/01/missed-the-magnificent-seven-try-buying-these-3/",
            "time_published": "20240401T130000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "All three companies have very long runways for growth ahead.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768661/two-investors-consider-a-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.297572,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.166935",
                    "ticker_sentiment_score": "0.06688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.177046",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.111747",
                    "ticker_sentiment_score": "0.206816",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.177046",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.221313",
                    "ticker_sentiment_score": "0.128312",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Rise In Reaction To 'Good' Inflation Data",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-data-nvidia-ai-chip-ipo/",
            "time_published": "20240401T113600",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Rise After 'Good' Inflation Data. Nvidia AI Chip Peer Works On Base Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                }
            ],
            "overall_sentiment_score": 0.168314,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MEDP",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.21857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "-0.02974",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.08282",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.225093",
                    "ticker_sentiment_score": "0.166637",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.123951",
                    "ticker_sentiment_score": "0.071468",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RDDT",
                    "relevance_score": "0.02074",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.02074",
                    "ticker_sentiment_score": "0.203432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AXON",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.21857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.02074",
                    "ticker_sentiment_score": "0.150771",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.123951",
                    "ticker_sentiment_score": "0.027496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALAB",
                    "relevance_score": "0.123951",
                    "ticker_sentiment_score": "0.176455",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EWBC",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.21857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.184991",
                    "ticker_sentiment_score": "0.019752",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "-0.02974",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.02074",
                    "ticker_sentiment_score": "0.248366",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.21857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CYBR",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.264658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.21857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HUBS",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.264658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NET",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.264658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XIACY",
                    "relevance_score": "0.02074",
                    "ticker_sentiment_score": "-0.033494",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "-0.02974",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.041466",
                    "ticker_sentiment_score": "0.21857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.02074",
                    "ticker_sentiment_score": "0.203432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:NXT",
                    "relevance_score": "0.02074",
                    "ticker_sentiment_score": "0.203432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Meet The \"Magnificent Seven\" of Healthcare Stocks",
            "url": "https://www.fool.com/investing/2024/04/01/meet-the-magnificent-seven-of-healthcare-stocks/",
            "time_published": "20240401T083000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The tech sector doesn't have a monopoly on magnificent corporations.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770839/person-sitting-and-working-at-a-desk.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.24052,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABT",
                    "relevance_score": "0.042048",
                    "ticker_sentiment_score": "0.180009",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.125679",
                    "ticker_sentiment_score": "0.255601",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCA",
                    "relevance_score": "0.248259",
                    "ticker_sentiment_score": "0.115038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.207928",
                    "ticker_sentiment_score": "0.28535",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.167032",
                    "ticker_sentiment_score": "0.306284",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.167032",
                    "ticker_sentiment_score": "0.286408",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.207928",
                    "ticker_sentiment_score": "0.134207",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.207928",
                    "ticker_sentiment_score": "0.100054",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Have $1,500? 2 Top Growth Stocks to Buy Right Now for 2024 and Beyond",
            "url": "https://www.fool.com/investing/2024/03/31/have-1500-2-top-growth-stocks-to-buy-right-now/",
            "time_published": "20240331T134500",
            "authors": [
                "Rachel Warren"
            ],
            "summary": "Great companies in steadily growing industries can deliver enviable returns through the years.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770818/person-looking-thoughtfully-at-screen-computer.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999174"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.162909,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.361626",
                    "ticker_sentiment_score": "0.193373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.361626",
                    "ticker_sentiment_score": "0.229426",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Unstoppable Stocks to Buy Hand Over Fist in April",
            "url": "https://www.fool.com/investing/2024/03/30/unstoppable-stocks-to-buy-hand-over-fist-in-april/",
            "time_published": "20240330T105000",
            "authors": [
                "and Prosper Junior Bakiny",
                "David Jagielski",
                "Keith Speights"
            ],
            "summary": "These stocks have exceptionally bright prospects.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771014/happy-woman-because-the-stock-market-went-up.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.166515,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.293339",
                    "ticker_sentiment_score": "0.024678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.21193",
                    "ticker_sentiment_score": "0.117682",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Strong Before Inflation Data; Will Nvidia Peer Forge Base?",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-will-nvidia-ai-chip-ipo-forge-base/",
            "time_published": "20240328T205027",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Market Strong Before Inflation Data. Will Nvidia Peer Forge Base? Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                }
            ],
            "overall_sentiment_score": 0.175286,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MEDP",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.220043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "-0.070684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.090389",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.245115",
                    "ticker_sentiment_score": "0.214774",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.135221",
                    "ticker_sentiment_score": "0.074766",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RDDT",
                    "relevance_score": "0.022643",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.022643",
                    "ticker_sentiment_score": "0.2053",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AXON",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.220043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.022643",
                    "ticker_sentiment_score": "0.15234",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.135221",
                    "ticker_sentiment_score": "0.028776",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALAB",
                    "relevance_score": "0.135221",
                    "ticker_sentiment_score": "0.184368",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EWBC",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.220043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.135221",
                    "ticker_sentiment_score": "-0.019606",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.067855",
                    "ticker_sentiment_score": "-0.072171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.022643",
                    "ticker_sentiment_score": "0.250408",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.220043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CYBR",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.266176",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.220043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HUBS",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.266176",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NET",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.266176",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XIACY",
                    "relevance_score": "0.022643",
                    "ticker_sentiment_score": "-0.034813",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.067855",
                    "ticker_sentiment_score": "-0.072171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.045267",
                    "ticker_sentiment_score": "0.220043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.022643",
                    "ticker_sentiment_score": "0.2053",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:NXT",
                    "relevance_score": "0.022643",
                    "ticker_sentiment_score": "0.2053",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Top Biotech Buyout Candidates",
            "url": "https://www.zacks.com/commentary/2247682/2-top-biotech-buyout-candidates",
            "time_published": "20240328T175500",
            "authors": [
                "Andrew Rocco"
            ],
            "summary": "The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.182342,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.277748",
                    "ticker_sentiment_score": "0.202168",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.305633",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.136246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.477704",
                    "ticker_sentiment_score": "0.429519",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.04075",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.330286",
                    "ticker_sentiment_score": "0.29467",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Market Shows Breadth As Leaders Take A Breath: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-breadth-leaders-take-a-breath/",
            "time_published": "20240328T145250",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "The stock market rally was mixed in a holiday-shortened week. The Nasdaq fell modestly while the Russell 2000 rose solidly. Many AI and other growth leaders suffered solid to sharp losses. DraftKings ( DKNG ) fell sharply as the NCAA moved to ban special prop bets following claims regarding a pro ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-BullPortrait-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.04615,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.187949",
                    "ticker_sentiment_score": "-0.020614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.028481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UAL",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.072062",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.094638",
                    "ticker_sentiment_score": "-0.051824",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.094638",
                    "ticker_sentiment_score": "-0.021015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FLUT",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.011055",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.01012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.01012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNUT",
                    "relevance_score": "0.157073",
                    "ticker_sentiment_score": "-0.027108",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.125953",
                    "ticker_sentiment_score": "-0.037416",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.157073",
                    "ticker_sentiment_score": "0.012638",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NCLH",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.042335",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADBE",
                    "relevance_score": "0.094638",
                    "ticker_sentiment_score": "0.092167",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.01012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.042335",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.268541",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.125953",
                    "ticker_sentiment_score": "0.08374",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/news/24/03/37984981/heres-how-much-you-would-have-made-owning-eli-lilly-and-co-stock-in-the-last-5-years",
            "time_published": "20240328T143022",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Eli Lilly and Co LLY has outperformed the market over the past 5 years by 30.75% on an annualized basis producing an average annual return of 43.59%. Currently, Eli Lilly and Co has a market capitalization of $741.67 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.229957,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.949596",
                    "ticker_sentiment_score": "0.358087",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly vs. Berkshire Hathaway: Which Stock Will Become the Next Member of the $1 Trillion Club?",
            "url": "https://www.fool.com/investing/2024/03/28/eli-lilly-vs-berkshire-hathaway-which-stock-will-b/",
            "time_published": "20240328T130500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Don't assume that because Berkshire is worth nearly $900 billion, it's sure to get to $1 trillion first.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770397/stock-traders-looking-at-a-chart.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.208619,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.040012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.594159",
                    "ticker_sentiment_score": "0.395934",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "0.268975",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Bull Market Buys: 3 Dividend Stocks to Own for the Long Run",
            "url": "https://www.fool.com/investing/2024/03/28/bull-market-buys-3-dividend-stocks-to-own-for-the/",
            "time_published": "20240328T123000",
            "authors": [
                "Marc Rapport"
            ],
            "summary": "Invest in stability, dividends, and growth with these three accomplished real estate operators.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770757%2Freit-and-stock-chart.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.356204,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ARE",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.17707",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "T",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.149038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMT",
                    "relevance_score": "0.408791",
                    "ticker_sentiment_score": "0.153084",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.149038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.149038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "O",
                    "relevance_score": "0.298749",
                    "ticker_sentiment_score": "0.234734",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?",
            "url": "https://www.investors.com/news/technology/alzheimers-disease-treatments-eli-lilly-donanemab-amyloid-beta/",
            "time_published": "20240328T120021",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/TECHpic-brain-040124-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.036018,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "-0.071189",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALEC",
                    "relevance_score": "0.13414",
                    "ticker_sentiment_score": "0.151708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALNY",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INMB",
                    "relevance_score": "0.02695",
                    "ticker_sentiment_score": "-0.070252",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.264515",
                    "ticker_sentiment_score": "-0.024517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.107495",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "0.09074",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.041674",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "-0.025612",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "-0.068762",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock-Split Watch: Are These 2 Top Growth Stocks Next?",
            "url": "https://www.fool.com/investing/2024/03/28/stock-split-watch-are-these-2-top-growth-stocks/",
            "time_published": "20240328T120000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770130/physician-talking-to-patient.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99977"
                }
            ],
            "overall_sentiment_score": 0.213322,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.438836",
                    "ticker_sentiment_score": "0.259135",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.115509",
                    "ticker_sentiment_score": "0.242099",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.057907",
                    "ticker_sentiment_score": "0.219005",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Prediction: This Will Be the Next \"Magnificent Seven\" Stock",
            "url": "https://www.fool.com/investing/2024/03/28/this-will-be-next-magnificent-seven-stock/",
            "time_published": "20240328T105000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "This particular company's growth is set to take off...",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770699%2Fgettyimages-1191849990.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                }
            ],
            "overall_sentiment_score": 0.336254,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.140213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.140213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.149346",
                    "ticker_sentiment_score": "0.313833",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.140213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.09989",
                    "ticker_sentiment_score": "-0.018311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.191248",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "-0.063004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.653512",
                    "ticker_sentiment_score": "0.469235",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "-0.063004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.140213",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures: Small Caps Jump But Nvidia, Growth Leaders Retreat",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-small-caps-power-higher-nvidia-growth-leaders-retreat/",
            "time_published": "20240327T204100",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures: Small Caps Power Higher While Nvidia, Growth Leaders Retreat Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-bull-tongue-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.103096,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.138663",
                    "ticker_sentiment_score": "0.09456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.337657",
                    "ticker_sentiment_score": "-0.100758",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALAB",
                    "relevance_score": "0.138663",
                    "ticker_sentiment_score": "-0.074302",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.206685",
                    "ticker_sentiment_score": "-0.092805",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.206685",
                    "ticker_sentiment_score": "-0.075383",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EWBC",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.080418",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NCLH",
                    "relevance_score": "0.138663",
                    "ticker_sentiment_score": "0.053608",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.172836",
                    "ticker_sentiment_score": "-0.064357",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.206685",
                    "ticker_sentiment_score": "0.143742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.069596",
                    "ticker_sentiment_score": "0.080597",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.138663",
                    "ticker_sentiment_score": "-0.074302",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.034831",
                    "ticker_sentiment_score": "0.112676",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "US Companies In Japan Wary On Market Intervention As Yen Hits 34-Year Low Vs. Dollar - Chevron  ( NYSE:CVX ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37966781/us-companies-in-japan-wary-on-market-intervention-as-yen-hits-34-year-low-vs-dollar",
            "time_published": "20240327T175941",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "U.S. commodity exporters and pharmaceutical companies are among the top traders, with Japan casting a cautious eye toward the foreign exchange markets, in the coming days. Top exporters with significant Japanese interests include Exxon Mobil Corp XOM and Chevron Corp CVX.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Japanese-Yen-Bank-Note-With-Stock-Graph-_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.041021,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "-0.058002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "-0.075447",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.47126",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.284983",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.47126",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FOREX:JPY",
                    "relevance_score": "0.635246",
                    "ticker_sentiment_score": "-0.1938",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.531594",
                    "ticker_sentiment_score": "-0.06738",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking  ( VKTX )  Up 17% on Encouraging Oral Obesity Drug Data",
            "url": "https://www.zacks.com/stock/news/2246931/viking-vktx-up-17-on-encouraging-oral-obesity-drug-data",
            "time_published": "20240327T164200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.163942,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.338913",
                    "ticker_sentiment_score": "0.3268",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.245835",
                    "ticker_sentiment_score": "0.1314",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.197816",
                    "ticker_sentiment_score": "0.182347",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.292922",
                    "ticker_sentiment_score": "0.310708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly, IBD Stock Of The Day, Jumps Entry As Obesity Space Heats",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-weight-loss-drugs-viking-therapeutics-novo-nordisk/",
            "time_published": "20240327T162253",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly Stock Jumps Entry Point As Weight-Loss Drugs Fervor Heats Up Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/SOTD-3-27-2024LLY.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.189317,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.550532",
                    "ticker_sentiment_score": "0.3418",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "-0.032259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVCR",
                    "relevance_score": "0.06697",
                    "ticker_sentiment_score": "0.108936",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.030653",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amazon  ( AMZN )  Expands Same-Day Medication Delivery Service",
            "url": "https://www.zacks.com/stock/news/2246746/amazon-amzn-expands-same-day-medication-delivery-service",
            "time_published": "20240327T142300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Amazon (AMZN) expands same-day delivery of prescription medication to New York City and Los Angeles.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4d/2657.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.262472,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.190667",
                    "ticker_sentiment_score": "0.006074",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LTTHF",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.074045",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EBAY",
                    "relevance_score": "0.127795",
                    "ticker_sentiment_score": "0.130543",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.828466",
                    "ticker_sentiment_score": "0.49868",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "KR",
                    "relevance_score": "0.252332",
                    "ticker_sentiment_score": "0.207383",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly and Co's Options: A Look at What the Big Money is Thinking - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37959034/eli-lilly-and-cos-options-a-look-at-what-the-big-money-is-thinking",
            "time_published": "20240327T134621",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.94762"
                }
            ],
            "overall_sentiment_score": 0.078676,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.827318",
                    "ticker_sentiment_score": "0.106044",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Advances While Market Declines: Some Information for Investors",
            "url": "https://www.zacks.com/stock/news/2246297/eli-lilly-lly-advances-while-market-declines-some-information-for-investors",
            "time_published": "20240326T214519",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.158274,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.592095",
                    "ticker_sentiment_score": "0.175739",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.",
            "url": "https://www.investors.com/news/technology/dexcom-shows-market-leadership-with-jump-to-85-rs-rating/",
            "time_published": "20240326T175600",
            "authors": [
                "JAMES DETAR",
                "INVESTOR'S BUSINESS DAILY",
                "Investor's Business Daily"
            ],
            "summary": "Dexcom Stock A Leader. Prognosis Good Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-Diabetes-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999922"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                }
            ],
            "overall_sentiment_score": 0.241901,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.180181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LFMD",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ITGR",
                    "relevance_score": "0.196877",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.63935",
                    "ticker_sentiment_score": "0.28814",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.180181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly - Biohaven  ( NYSE:BHVN ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37942782/obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff",
            "time_published": "20240326T174838",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Monday, Biohaven's BHVN CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company's experimental obesity drug. Biohaven said it is developing an obesity drug that works differently from Novo Nordisk A/S's NVO and Eli Lilly And Co's LLY popular GLP-1 drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Doctor-Measuring-Obese-Man-Waist-Body-Fa_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.072644,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.120107",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.588876",
                    "ticker_sentiment_score": "0.136685",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.239247",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Viking jumped 25% on early weight loss pill data. We still prefer Eli Lilly",
            "url": "https://www.cnbc.com/2024/03/26/viking-jumped-25percent-on-weight-loss-pill-data-we-still-prefer-eli-lilly-.html",
            "time_published": "20240326T152355",
            "authors": [
                "Jeff Marks"
            ],
            "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107370511-1707341806087-gettyimages-880238778-98622912.jpeg?v=1711380276&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.180571,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "0.08036",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "0.150186",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.420083",
                    "ticker_sentiment_score": "0.214901",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "0.08036",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "CHMP to Delay Nod on Biogen  ( BIIB ) , Eisai's Alzheimer's Drug",
            "url": "https://www.zacks.com/stock/news/2246241/chmp-to-delay-nod-on-biogen-biib-eisais-alzheimers-drug",
            "time_published": "20240326T152100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.070826,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.052298",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANIP",
                    "relevance_score": "0.253514",
                    "ticker_sentiment_score": "0.165783",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.301933",
                    "ticker_sentiment_score": "-0.021795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.301933",
                    "ticker_sentiment_score": "0.223693",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.349153",
                    "ticker_sentiment_score": "0.225126",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street Awaits Consumer Confidence Data",
            "url": "https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data",
            "time_published": "20240326T142100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility. The AI-driven rally of the last 15 months is showing no sign of losing pace.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.097535,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.069557",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.248682",
                    "ticker_sentiment_score": "0.080175",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.069557",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.039322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "-0.176937",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Viking Surges After Weight-Loss Pill Beats Forecasts In Just 28 Days",
            "url": "https://www.investors.com/news/technology/viking-stock-weight-loss-drug-zepbound-wegovy/",
            "time_published": "20240326T130240",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Viking Stock Surges After Weight-Loss Drug Tops Expectations Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-drugTest-09-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.033581,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.451494",
                    "ticker_sentiment_score": "-0.104446",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MASI",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "-0.187987",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.310843",
                    "ticker_sentiment_score": "-0.315044",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "-0.152404",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NKTX",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.451494",
                    "ticker_sentiment_score": "-0.104446",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
            "url": "https://www.zacks.com/stock/news/2245863/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings",
            "time_published": "20240326T125011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default5.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999756"
                }
            ],
            "overall_sentiment_score": 0.385942,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.390904",
                    "ticker_sentiment_score": "0.418501",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.266828",
                    "ticker_sentiment_score": "0.271409",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
            "url": "https://www.zacks.com/stock/news/2245797/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
            "time_published": "20240326T102006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default11.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.219275,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.088153",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "0.069712",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "0.069712",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "0.069712",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?",
            "url": "https://www.fool.com/investing/2024/03/26/best-stock-eli-lilly-novo-nordisk-viking/",
            "time_published": "20240326T095100",
            "authors": [
                "Keith Speights"
            ],
            "summary": "All three of these high-flying stocks could have more room to run.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770468/ozempic.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.192686,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.28387",
                    "ticker_sentiment_score": "0.288063",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.191549",
                    "ticker_sentiment_score": "0.1832",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.048327",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.372216",
                    "ticker_sentiment_score": "0.150081",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street Set to Post Fifth Winning Month Amid Volatility",
            "url": "https://www.zacks.com/stock/news/2245743/wall-street-set-to-post-fifth-winning-month-amid-volatility",
            "time_published": "20240326T063300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Wall Street is likely to record the fifth consecutive winning month despite volatility.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d3/848.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.099917,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.072406",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.248682",
                    "ticker_sentiment_score": "0.08021",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.072406",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.039322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "-0.176937",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Futures Fall With Market At Highs; 3 Stocks Near Buy Points",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fed-ai-boom-drive/",
            "time_published": "20240325T111338",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures Fall: Fed, AI Boom Keep Driving Stock Market. 3 Stocks Near Buy Points Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Federal-Reserve-fall-12-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.211205,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.234968",
                    "ticker_sentiment_score": "0.161222",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.346077",
                    "ticker_sentiment_score": "0.228016",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.263309",
                    "ticker_sentiment_score": "0.192294",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.177367",
                    "ticker_sentiment_score": "0.059004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.08924",
                    "ticker_sentiment_score": "-0.097246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.08924",
                    "ticker_sentiment_score": "-0.097246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.118793",
                    "ticker_sentiment_score": "0.105486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MU",
                    "relevance_score": "0.059562",
                    "ticker_sentiment_score": "0.287018",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.148182",
                    "ticker_sentiment_score": "0.050944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.118793",
                    "ticker_sentiment_score": "-0.134343",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.059562",
                    "ticker_sentiment_score": "0.105167",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk and Eli Lilly May Finally Have Some Real Competition",
            "url": "https://www.fool.com/investing/2024/03/25/novo-nordisk-and-eli-lilly-may-finally-have-some-r/",
            "time_published": "20240325T102500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769906%2Fgettyimages-1346675569.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.27397,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.319725",
                    "ticker_sentiment_score": "0.210402",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.319725",
                    "ticker_sentiment_score": "0.210402",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.379051",
                    "ticker_sentiment_score": "0.353895",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
            "url": "https://www.zacks.com/stock/news/2245284/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
            "time_published": "20240325T102007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.303397,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.063944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.127429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.089069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.063944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.063944",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Best Stocks to Invest $10,000 in Right Now",
            "url": "https://www.fool.com/investing/2024/03/25/the-best-stocks-to-invest-10000-in-right-now/",
            "time_published": "20240325T075500",
            "authors": [
                "Joe Tenebruso"
            ],
            "summary": "These elite enterprises can help you grow richer.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770331/investor-gettyimages-1125967385.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.36328,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.179479",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.115837",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.380978",
                    "ticker_sentiment_score": "0.378059",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.132272",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "59% of This Vanguard ETF Is Invested in the \"Magnificent Seven\" Stocks. Is It a No-Brainer Buy Right Now?",
            "url": "https://www.fool.com/investing/2024/03/24/vanguard-etf-magnificent-seven-buy-right-now/",
            "time_published": "20240324T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "If you want to own all of the Magnificent Seven stocks plus other megacap winners, this ETF could be right up your alley.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770060%2Fetf-board-and-person.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999937"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.351336,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.187514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.178665",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.218182",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.187514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.178665",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.043078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.043078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRCX",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.043078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.178665",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.043078",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Two Tailwinds Continue To Fuel Market; 3 Stocks Setting Up Again",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-dovish-fed-nvidia-ai-boom-new-highs/",
            "time_published": "20240322T205833",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures: Dovish Fed, Nvidia-Led AI Boom Keep Driving Stock Market. 3 Stocks Near Buy Points Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Federal-Reserve-fall-12-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.257842,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.17094",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.342631",
                    "ticker_sentiment_score": "0.238243",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.283323",
                    "ticker_sentiment_score": "0.203655",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.062342",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.109337",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MU",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.288282",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.159781",
                    "ticker_sentiment_score": "0.053405",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.105524",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/news/24/03/37894869/comparative-study-eli-lilly-and-co-and-industry-competitors-in-pharmaceuticals-industry",
            "time_published": "20240322T160014",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Eli Lilly and Co LLY and its primary competitors in the Pharmaceuticals industry.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.189915,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.48182",
                    "ticker_sentiment_score": "0.231327",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37892677/ozempic-users-speak-out-over-side-effects-lawsuits-against-novo-nordisk-and-eli-lilly-surge",
            "time_published": "20240322T143416",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co LLY and Novo Nordisk A/S NVS, alleging severe complications after taking their medications to manage diabetes and aid weight loss.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ozempic-shutter_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.051356,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.354319",
                    "ticker_sentiment_score": "-0.213025",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.354319",
                    "ticker_sentiment_score": "-0.171064",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.181819",
                    "ticker_sentiment_score": "0.126752",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?",
            "url": "https://www.fool.com/investing/2024/03/22/with-shares-near-all-time-highs-is-it-a-buy/",
            "time_published": "20240322T143000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769867%2Fgettyimages-1434356176.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.31419,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.179788",
                    "ticker_sentiment_score": "0.159365",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.069977",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.134156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.573651",
                    "ticker_sentiment_score": "0.473332",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.168048",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.168048",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Learn How The Best Mutual Funds Deliver Benchmark-Beating Returns",
            "url": "https://www.investors.com/etfs-and-funds/mutual-funds/best-performing-mutual-funds-2024-beat-benchmarks/",
            "time_published": "20240322T123014",
            "authors": [
                "ADAM SHELL",
                "Investor's Business Daily"
            ],
            "summary": "Best Performing Mutual Funds Top Benchmarks Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/w.Vitrus032524eps-300x127.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                }
            ],
            "overall_sentiment_score": 0.312476,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.025219",
                    "ticker_sentiment_score": "0.136201",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVMI",
                    "relevance_score": "0.025219",
                    "ticker_sentiment_score": "0.051195",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.050412",
                    "ticker_sentiment_score": "0.108971",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.025219",
                    "ticker_sentiment_score": "0.136201",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LASR",
                    "relevance_score": "0.03782",
                    "ticker_sentiment_score": "-0.124863",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXPI",
                    "relevance_score": "0.025219",
                    "ticker_sentiment_score": "0.087165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.025219",
                    "ticker_sentiment_score": "0.136201",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.012611",
                    "ticker_sentiment_score": "0.164502",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.012611",
                    "ticker_sentiment_score": "0.046671",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRVL",
                    "relevance_score": "0.025219",
                    "ticker_sentiment_score": "0.087165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.012611",
                    "ticker_sentiment_score": "0.079997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.03782",
                    "ticker_sentiment_score": "0.24374",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Did Eli Lilly Just One-Up Novo Nordisk?",
            "url": "https://www.fool.com/investing/2024/03/22/did-eli-lilly-just-one-up-novo-nordisk/",
            "time_published": "20240322T111500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769751%2Fgettyimages-1434715649.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.400436,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.849481",
                    "ticker_sentiment_score": "0.572617",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.076358",
                    "ticker_sentiment_score": "0.061272",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.434763",
                    "ticker_sentiment_score": "0.164846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Could Viking Therapeutics Become the Next Eli Lilly?",
            "url": "https://www.fool.com/investing/2024/03/22/could-viking-therapeutics-become-next-eli-lilly/",
            "time_published": "20240322T085500",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Viking shares have skyrocketed on its recent good news.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770100%2Fgettyimages-1220595235.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.459462"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.153814,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.050894",
                    "ticker_sentiment_score": "0.123928",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.556298",
                    "ticker_sentiment_score": "0.243268",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.151858",
                    "ticker_sentiment_score": "0.02695",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medicare Will Cover Weight-Loss Drugs - For Some People",
            "url": "https://www.investors.com/news/technology/weight-loss-drugs-wegovy-zepbound-eli-lilly-novo-nordisk/",
            "time_published": "20240321T190934",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Weight-Loss Drugs Win Medicare Coverage. Here's What It Means For Novo Nordisk, Eli Lilly Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/Stock-Medical-04-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.118183,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.554365",
                    "ticker_sentiment_score": "0.003392",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.297061",
                    "ticker_sentiment_score": "-0.0594",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37876911/wegovys-success-medicare-contemplates-covering-novo-nordisks-semaglutide-for-heart-health",
            "time_published": "20240321T172309",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "In a significant development, Medicare may extend coverage for Novo Nordisk A/S's NVO weight-loss drug Wegovy ( semaglutide ) to certain members with a history of heart disease.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_7.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.142358,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.167904",
                    "ticker_sentiment_score": "-0.061371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.403913",
                    "ticker_sentiment_score": "0.435666",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37859130/is-eli-lilly-winning-the-war-on-weight-loss-drugs-zepbound-overtakes-wegovy-in-us-prescriptions",
            "time_published": "20240320T210000",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "Eli Lilly and Co. LLY enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound - the latter already recording stellar sales only three months after launch in December. Recent data showed that, for the first time since launch, Zepbound filled more U.S. prescriptions in a single ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.111981,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.388879",
                    "ticker_sentiment_score": "0.194942",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.16117",
                    "ticker_sentiment_score": "-0.1407",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.081001",
                    "ticker_sentiment_score": "0.07224",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Fusion  ( FUSN )  Up 99% on $2.4B Buyout Offer From AstraZeneca",
            "url": "https://www.zacks.com/stock/news/2243681/fusion-fusn-up-99-on-24b-buyout-offer-from-astrazeneca",
            "time_published": "20240320T172100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.175598,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.273552",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.338119",
                    "ticker_sentiment_score": "0.300363",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.459624",
                    "ticker_sentiment_score": "0.233351",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?",
            "url": "https://www.investors.com/news/technology/pfizer-stock-buy-now/",
            "time_published": "20240320T170719",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/PFE-evergreen-051419-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999981"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999976"
                }
            ],
            "overall_sentiment_score": 0.120598,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "-0.125315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "-0.125315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVAX",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "0.075008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "0.075008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "-0.14606",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.687052",
                    "ticker_sentiment_score": "0.203831",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "0.059184",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "-0.14606",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly and Co's Options Frenzy: What You Need to Know - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37847944/eli-lilly-and-cos-options-frenzy-what-you-need-to-know",
            "time_published": "20240320T140206",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.107187,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.76213",
                    "ticker_sentiment_score": "0.106972",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?",
            "url": "https://www.fool.com/investing/2024/03/20/novo-nordisk-versus-eli-lilly/",
            "time_published": "20240320T123000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "The gap has been shrinking between these stocks over the past month.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769568/a-doctor-using-a-stethoscope.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.119613,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.412861",
                    "ticker_sentiment_score": "0.219186",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.622414",
                    "ticker_sentiment_score": "0.216856",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss",
            "url": "https://www.investors.com/etfs-and-funds/etfs/weight-loss-drugs-feisty-rivals-take-on-eli-lilly-novo-nordisk/",
            "time_published": "20240320T120048",
            "authors": [
                "MATT KRANTZ",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/Stock-weightlossdrug-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995869"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.296034,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.365148",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.254973",
                    "ticker_sentiment_score": "0.274537",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.171325",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KROS",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.2681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.374312",
                    "ticker_sentiment_score": "0.428918",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "0.242652",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MLYS",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.2681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics",
            "url": "https://www.zacks.com/stock/news/2243165/zacks-investment-ideas-feature-highlights-apple-alphabet-eli-lilly-novo-nordisk-and-viking-therapeutics",
            "time_published": "20240320T085400",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.031421,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.466811",
                    "ticker_sentiment_score": "0.006101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.070935",
                    "ticker_sentiment_score": "0.074881",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.672533",
                    "ticker_sentiment_score": "0.041285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.210579",
                    "ticker_sentiment_score": "0.06704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.466811",
                    "ticker_sentiment_score": "0.006101",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Surpasses Market Returns: Some Facts Worth Knowing",
            "url": "https://www.zacks.com/stock/news/2243059/eli-lilly-lly-surpasses-market-returns-some-facts-worth-knowing",
            "time_published": "20240319T214520",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly (LLY) closed the most recent trading day at $772.78, moving +1.33% from the previous trading session.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default276.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.185834,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.543535",
                    "ticker_sentiment_score": "0.280139",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Time to be \"Overweight\" Viking Therapeutics",
            "url": "https://www.zacks.com/commentary/2243036/time-to-be-overweight-viking-therapeutics",
            "time_published": "20240319T185800",
            "authors": [
                "Andrew Rocco"
            ],
            "summary": "A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.008889",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.113166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.673107",
                    "ticker_sentiment_score": "0.048942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.148456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.123249",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.008889",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On' - Datadog  ( NASDAQ:DDOG ) , Altimmune  ( NASDAQ:ALT ) ",
            "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/03/37812350/cramer-calls-datadog-dynamite-puts-sofi-in-dog-house-what-the-heck-is-going-on",
            "time_published": "20240319T135514",
            "authors": [
                "Avi Kapoor"
            ],
            "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Marvell Technology, Inc. MRVL reported a mixed quarter. \"We got to wait,\" he added.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/19/datadog_cramer.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.26512,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LNTH",
                    "relevance_score": "0.31583",
                    "ticker_sentiment_score": "0.312008",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DDOG",
                    "relevance_score": "0.31583",
                    "ticker_sentiment_score": "0.294909",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.16117",
                    "ticker_sentiment_score": "0.139368",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.239698",
                    "ticker_sentiment_score": "0.244588",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SOFI",
                    "relevance_score": "0.239698",
                    "ticker_sentiment_score": "-0.042238",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RDNT",
                    "relevance_score": "0.16117",
                    "ticker_sentiment_score": "0.272036",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRVL",
                    "relevance_score": "0.31583",
                    "ticker_sentiment_score": "0.216086",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.16117",
                    "ticker_sentiment_score": "0.204587",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:RON",
                    "relevance_score": "0.081001",
                    "ticker_sentiment_score": "0.262039",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Biotech Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover",
            "url": "https://www.investors.com/news/technology/fusion-pharmaceuticals-astrazeneca-acquisition-biotech-stock/",
            "time_published": "20240319T130332",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Fusion Pharmaceuticals Scores $2 Billion AstraZeneca Takeover. Biotech Stock Nearly Doubles Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                }
            ],
            "overall_sentiment_score": -0.024011,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.329551",
                    "ticker_sentiment_score": "-0.283901",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "-0.146994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "-0.19295",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
            "url": "https://www.zacks.com/stock/news/2242689/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
            "time_published": "20240319T130016",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default345.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.224118,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.532696",
                    "ticker_sentiment_score": "0.154837",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?",
            "url": "https://www.forbes.com/sites/greatspeculations/2024/03/19/should-you-pick-eli-lilly-stock-after-a-4x-rise-in-three-years/",
            "time_published": "20240319T120031",
            "authors": [
                "Trefis Team"
            ],
            "summary": "Eli Lilly stock ( NYSE: LLY ) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year period. This can primarily be attributed to a significant 236% rise in the company's P/S ratio to ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65f933b2ce306ad3e0975eb8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.317785,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.702129",
                    "ticker_sentiment_score": "0.562014",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.075397",
                    "ticker_sentiment_score": "0.229058",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Did Novo Nordisk Just Get a Jump on Eli Lilly?",
            "url": "https://www.fool.com/investing/2024/03/19/did-novo-nordisk-just-say-checkmate-to-eli-lilly/",
            "time_published": "20240319T113000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "A recent FDA announcement may have just put one company in the lead.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769494%2Fmedicine-pills-fda-approval-stamp.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.260153,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.308504",
                    "ticker_sentiment_score": "0.189617",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.091571",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.47452",
                    "ticker_sentiment_score": "0.420823",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Why Is Fusion Pharmaceuticals Stock Trading Higher Today? - AstraZeneca  ( NASDAQ:AZN ) , Fusion Pharmaceuticals  ( NASDAQ:FUSN ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37818128/astrazenecas-2-4b-fusion-pharmaceuticals-acquisition-signals-shift-in-efforts-from-traditional-re",
            "time_published": "20240319T112623",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Tuesday, AstraZeneca Plc AZN agreed to acquire Fusion Pharmaceuticals Inc FUSN for $21.00 per share in cash plus a non-transferable contingent value right ( CVR ) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/AstraZeneca-HQ-in-Cambridge-UK_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.184623,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.111362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.281153",
                    "ticker_sentiment_score": "0.456567",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.368773",
                    "ticker_sentiment_score": "0.316525",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.201946",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
            "url": "https://www.zacks.com/stock/news/2242578/should-you-invest-in-the-vanguard-health-care-etf-vht",
            "time_published": "20240319T102005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default75.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.250395,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.064508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.125823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.064508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.064508",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?",
            "url": "https://www.fool.com/investing/2024/03/19/madrigal-eli-lilly-novo-nordisk-better-stock-buy/",
            "time_published": "20240319T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Madrigal has one key advantage over its two huge potential future rivals.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769602/fda-blocks-in-hand.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.188805,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.047185",
                    "ticker_sentiment_score": "0.113464",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.558244",
                    "ticker_sentiment_score": "0.256798",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.094204",
                    "ticker_sentiment_score": "0.25377",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.484881",
                    "ticker_sentiment_score": "0.272744",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37785607/us-prescriptions-race-for-weight-loss-drugs-eli-lillys-zepbound-overtakes-novo-nordisks-wegovy",
            "time_published": "20240318T142139",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co's LLY much-in-demand weight-loss drug Zepbound ( tirzepatide ) surged ahead with 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk A/S's NVO rival obesity medicine Wegovy ( semglutide ) for the first time since its launch.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.083401,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.197413",
                    "ticker_sentiment_score": "0.062231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.468029",
                    "ticker_sentiment_score": "-0.003071",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.212439",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "-0.027466",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead",
            "url": "https://www.fool.com/investing/2024/03/18/forget-eli-lilly-buy-this-magnificent-biotech-stoc/",
            "time_published": "20240318T060000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "This company's growth story is about to get moving with gusto.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769498/investors-discuss-investment-at-table.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.169366,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.241596",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IOVA",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.289351",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Unstoppable Stocks You Can Buy Now Without Any Hesitation",
            "url": "https://www.fool.com/investing/2024/03/17/3-unstoppable-stocks-you-can-buy-now-without-any/",
            "time_published": "20240317T130000",
            "authors": [
                "Keith Speights",
                "and Prosper Junior Bakiny",
                "David Jagielski"
            ],
            "summary": "There's no need for delays in buying these great stocks.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769331/young-woman-smiling-hands-behind-head.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.127458,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.2256",
                    "ticker_sentiment_score": "-0.115588",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "-0.165219",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.367141",
                    "ticker_sentiment_score": "0.252288",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock?",
            "url": "https://www.fool.com/investing/2024/03/17/eli-lilly-taps-amazon-to-deliver-its-weight-manage/",
            "time_published": "20240317T072400",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Free two-day shipping for Prime members and a direct-to-consumer sales model could accelerate sales of Eli Lilly's Zepbound.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769141%2Finvestor-looks-worried-at-computer-in-a-living-room-setting-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.237044,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.51768",
                    "ticker_sentiment_score": "0.326446",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.03811",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.221313",
                    "ticker_sentiment_score": "0.322193",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.111747",
                    "ticker_sentiment_score": "0.043944",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Trillion-Dollar Crystal Ball: 3 Companies Next in Line for the Market Milestone",
            "url": "https://markets.businessinsider.com/news/stocks/the-trillion-dollar-crystal-ball-3-companies-next-in-line-for-the-market-milestone-1033169865",
            "time_published": "20240316T180000",
            "authors": [
                "Rick Orford"
            ],
            "summary": "There are only six trillion-dollar stocks worldwide, every one of which is a popular name. And they all rightfully sit at the top of their sectors. There's a certain allure to reaching $1 trillion, and investors are always looking for the next one to breach that valuation.",
            "banner_image": "https://investorplace.com/wp-content/uploads/2022/12/brk-3-300x169.jpg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999822"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.249159,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.041828",
                    "ticker_sentiment_score": "0.133089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.041828",
                    "ticker_sentiment_score": "0.133089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.041828",
                    "ticker_sentiment_score": "0.219729",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.041828",
                    "ticker_sentiment_score": "0.133089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.041828",
                    "ticker_sentiment_score": "0.219729",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.083541",
                    "ticker_sentiment_score": "0.161462",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.125025",
                    "ticker_sentiment_score": "0.158757",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Just Had a Setback. Is Its Stock Still a Buy?",
            "url": "https://www.fool.com/investing/2024/03/16/eli-lilly-just-had-a-setback-is-its-stock-still-a/",
            "time_published": "20240316T131500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The drugmaker is caught up in an unexpected situation with regulators.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769169/stressed-investor-at-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.050877,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.151333",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "-0.095282",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Partners With Amazon's Pharmacy Business: Here's Why Both Stocks Should Win From the Deal",
            "url": "https://www.fool.com/investing/2024/03/16/eli-lilly-partners-with-amazons-pharmacy-business/",
            "time_published": "20240316T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "The world's biggest drugmaker has joined forces with the world's biggest online pharmacy provider.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769205/older-man-pills-laptop_gettyimages-1183769809.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.322301,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.696714",
                    "ticker_sentiment_score": "0.476707",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.858597",
                    "ticker_sentiment_score": "0.478987",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 20 Years - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/news/24/03/37757358/heres-how-much-you-would-have-made-owning-eli-lilly-and-co-stock-in-the-last-20-years",
            "time_published": "20240315T190025",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Eli Lilly and Co LLY has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return of 12.84%. Currently, Eli Lilly and Co has a market capitalization of $713.27 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.229957,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.949596",
                    "ticker_sentiment_score": "0.358087",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Nasdaq, S&P 500 Extend Losses; Adobe Sell-Off Casts Pall On Tech; Ulta Beauty Tumbles",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-adobe-stock/",
            "time_published": "20240315T144448",
            "authors": [
                "KEN SHREVE",
                "Investor's Business Daily"
            ],
            "summary": "Nasdaq, S&P 500 Extend Losses. Adobe Sell-Off Casts Pall On Tech. Ulta Beauty Tumbles Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-MarketBoard-Blue42-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999921"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.073182,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.128398",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSTR",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.077214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "-0.001903",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ULTA",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.080304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.242862",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ADBE",
                    "relevance_score": "0.305058",
                    "ticker_sentiment_score": "0.011581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.242862",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.242862",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CLSK",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.077214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.077214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "-0.103425",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More",
            "url": "https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azns-new-acquisition-fda-updates-for-nvo-lly-and-more",
            "time_published": "20240315T131900",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.200599,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "0.06412",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.169378",
                    "ticker_sentiment_score": "0.118514",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.105455",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.210823",
                    "ticker_sentiment_score": "0.128918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "0.083978",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Can Eli Lilly Stock Double in 5 Years? Here's What It Would Take.",
            "url": "https://www.fool.com/investing/2024/03/15/can-eli-lilly-stock-double-in-5-years-heres-what/",
            "time_published": "20240315T131500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "The company's valuation may be high but that doesn't mean Eli Lilly is anywhere near its peak.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768802/a-doctor-looking-at-a-tablet-with-another-person.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.261434,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.601928",
                    "ticker_sentiment_score": "0.3645",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.012002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.042051",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Move Over, Tesla! These 6 Stocks Could Replace It in the \"Magnificent 7\"",
            "url": "https://www.fool.com/investing/2024/03/15/move-over-tesla-these-6-stocks-could-replace-it-in/",
            "time_published": "20240315T114600",
            "authors": [
                "Justin Pope"
            ],
            "summary": "Tesla is failing to keep pace with the rest of the Magnificent Seven.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769058/brk-4.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.308524,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.202585",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.202585",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.20537",
                    "ticker_sentiment_score": "0.246414",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.095498",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.181921",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.092116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.255106",
                    "ticker_sentiment_score": "0.030308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.093536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.3038",
                    "ticker_sentiment_score": "0.258595",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.3038",
                    "ticker_sentiment_score": "0.237763",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?",
            "url": "https://www.fool.com/investing/2024/03/15/pfizer-viking-therapeutics-eli-lilly-novo-nordisk/",
            "time_published": "20240315T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Viking Therapeutics just might be an attractive acquisition target for Pfizer.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769056/big-fish-eating-little-fish.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.143119,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.168884",
                    "ticker_sentiment_score": "0.149347",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.16697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.212839",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.168884",
                    "ticker_sentiment_score": "0.149347",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.823212",
                    "ticker_sentiment_score": "0.234987",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37716166/congressional-scrutiny-intensifies-on-chinese-biotech-firms-wuxi-apptec-faces-biotech-exodus",
            "time_published": "20240314T200301",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization ( BIO ) , a U.S. industry lobbying group, severs ties with the Chinese biotech.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/US-China-Tatiana-Popova-and-rawf8-by-Shu.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": -0.065123,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.259267",
                    "ticker_sentiment_score": "0.106372",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WXXWY",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "-0.033926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WUXAY",
                    "relevance_score": "0.340915",
                    "ticker_sentiment_score": "-0.06817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.069834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.069834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.083857",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amazon  ( AMZN )  Boosts Pharmacy Efforts With Lilly's Partnership",
            "url": "https://www.zacks.com/stock/news/2240963/amazon-amzn-boosts-pharmacy-efforts-with-lillys-partnership",
            "time_published": "20240314T155000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Amazon (AMZN) teams up with Lilly to deliver drug prescriptions that are sent to the latter's direct-to-consumer service, LillyDirect.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4d/2657.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.233733,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.284696",
                    "ticker_sentiment_score": "0.093314",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EBAY",
                    "relevance_score": "0.144708",
                    "ticker_sentiment_score": "0.094316",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.798255",
                    "ticker_sentiment_score": "0.459306",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "KR",
                    "relevance_score": "0.284696",
                    "ticker_sentiment_score": "0.155542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Lilly  ( LLY )  Partners Amazon to Deliver Drugs Like Zepbound",
            "url": "https://www.zacks.com/stock/news/2240711/lilly-lly-partners-amazon-to-deliver-drugs-like-zepbound",
            "time_published": "20240314T135400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.235264,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.709611",
                    "ticker_sentiment_score": "0.264861",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.402941",
                    "ticker_sentiment_score": "0.151039",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.208464",
                    "ticker_sentiment_score": "0.296485",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should Investors Worry About Eli Lilly's Latest Regulatory Setback?",
            "url": "https://www.fool.com/investing/2024/03/14/should-investors-worry-about-eli-lillys-latest-reg/",
            "time_published": "20240314T123000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "There are good reasons to remain optimistic.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768907/doctor-and-patient-talking.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.155591,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.510952",
                    "ticker_sentiment_score": "0.288214",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Experts hesitate on weight loss ETFs amid the obesity drug boom",
            "url": "https://www.cnbc.com/2024/03/13/weight-loss-etfs-may-sit-out-obesity-drug-mania-experts-say.html",
            "time_published": "20240313T230001",
            "authors": [
                "Anna Gleason"
            ],
            "summary": "While weight loss drugmakers are catching a bid with investors, experts are less certain that ETFs linked to the category can achieve the same success.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107385852-1710189287ETF-SEG2-031124.jpg?v=1710189286&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.818451"
                }
            ],
            "overall_sentiment_score": 0.108075,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.509589",
                    "ticker_sentiment_score": "0.185424",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.509589",
                    "ticker_sentiment_score": "0.185424",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Ascends While Market Falls: Some Facts to Note",
            "url": "https://www.zacks.com/stock/news/2240274/eli-lilly-lly-ascends-while-market-falls-some-facts-to-note",
            "time_published": "20240313T214519",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly (LLY) reachead $757.84 at the closing of the latest trading day, reflecting a +0.38% change compared to its last close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default306.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.192562,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.580956",
                    "ticker_sentiment_score": "0.249981",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Lilly Teams Up With Amazon To Deliver Weight-Loss Drug",
            "url": "https://www.investors.com/news/technology/eli-lilly-amazon-pharmacy-lillydirect-weight-loss-drug-zepbound/",
            "time_published": "20240313T171932",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Eli Lilly Taps Amazon Pharmacy To Help Deliver Weight-Loss Drug, Zepbound Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-Lilly-01-Shutterstock.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.035732,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.075635",
                    "ticker_sentiment_score": "-0.041654",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.552443",
                    "ticker_sentiment_score": "-0.070742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.075635",
                    "ticker_sentiment_score": "-0.242397",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.364987",
                    "ticker_sentiment_score": "0.088979",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.150592",
                    "ticker_sentiment_score": "-0.127667",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs - Agilent Technologies  ( NYSE:A ) , Avantor  ( NYSE:AVTR ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37668318/top-7-biotech-winners-of-novo-nordisk-eli-lillys-outsourcing-strategy-for-weight-lo",
            "time_published": "20240313T163538",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates. Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting it ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Genetic-Research-And-Biotech-Science-Con_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.276455,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "A",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.114066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WUXAY",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "0.139069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.072735",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APG",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.107571",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.238913",
                    "ticker_sentiment_score": "0.03309",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.387674",
                    "ticker_sentiment_score": "0.279985",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVTR",
                    "relevance_score": "0.238913",
                    "ticker_sentiment_score": "0.189468",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DHR",
                    "relevance_score": "0.238913",
                    "ticker_sentiment_score": "0.34917",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/dexcom-stock-buy-zone-diabetes-obesity-continuous-glucose-monitors/",
            "time_published": "20240313T160442",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/SOTD-3-13-24DXCM.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996023"
                }
            ],
            "overall_sentiment_score": 0.138038,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.053149",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.10132",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.10132",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "-0.23901",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.531326",
                    "ticker_sentiment_score": "0.152339",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.053149",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharmaceutical Crime Jumps 50% As Criminals Seek To Capitalize Rising Tide of Counterfeit Weight-Loss Drugs - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37662893/pharmaceutical-crime-jumps-50-as-criminals-seek-to-capitalize-rising-tide-of-counterfeit-weight-l",
            "time_published": "20240313T143118",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medications has intensified.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/OZempic-Insulin_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.134047,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "-0.088767",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.358152",
                    "ticker_sentiment_score": "0.130736",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 No-Brainer Stocks I'd Add to the \"Magnificent Seven\"",
            "url": "https://www.fool.com/investing/2024/03/13/2-no-brainer-stocks-id-add-to-magnificent-seven/",
            "time_published": "20240313T134500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "They fit right in.",
            "banner_image": "https://media.ycharts.com/charts/e88a70f1dbaeb58217edf59cea01b1d9.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.394698,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.22383",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.508232",
                    "ticker_sentiment_score": "0.4881",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.096535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.167998",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.228793",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.167998",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.126736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.338251",
                    "ticker_sentiment_score": "0.465553",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Obesity Drugs On Amazon - Eli Lilly Partners With Amazon's Pharmacy Unit To Deliver Drug Prescriptions, Including Popular Zepbound For Weight Loss - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37657277/obesity-drugs-on-amazon-eli-lilly-partners-with-amazons-pharmacy-unit-to-deliver-drug-prescriptio",
            "time_published": "20240313T124123",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Amazon.com's AMZN Amazon Pharmacy has integrated Eli Lilly And Co's LLY LillyDirect into its services, enabling home delivery of select medications for diabetes, obesity, and migraine.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Amazon-Pharmacy.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.059333,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.872847",
                    "ticker_sentiment_score": "0.152367",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.502207",
                    "ticker_sentiment_score": "0.357358",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?",
            "url": "https://www.fool.com/investing/2024/03/13/could-viking-therapeutics-challenge-eli-lilly/",
            "time_published": "20240313T090300",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Viking aims to enter a market that may be worth $100 billion in a few years.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769012%2Fgettyimages-doctors-talking.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.185992,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.50287",
                    "ticker_sentiment_score": "0.280042",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.316184",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.131463",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.195025",
                    "ticker_sentiment_score": "-0.046408",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer Says Tuesday Rally Was Driven By Nvidia, Eli Lilly And Other 'Stocks Reacting Positively To Good Earnings Per Share News' - Costco Wholesale  ( NASDAQ:COST ) , Broadcom  ( NASDAQ:AVGO ) ",
            "url": "https://www.benzinga.com/markets/equities/24/03/37648583/jim-cramer-says-tuesday-rally-was-driven-by-nvidia-eli-lilly-and-other-stocks-reacting-positivel",
            "time_published": "20240313T082542",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "U.S. stocks experienced a rise on Tuesday following consecutive losses for the S&P 500 and Nasdaq. What Happened: This positive turn occurred despite a slightly warmer-than-expected February consumer price index.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Financial-Analyst-Using-Smartphone-With-_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.344907,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.193465",
                    "ticker_sentiment_score": "-0.245996",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.28664",
                    "ticker_sentiment_score": "-0.004381",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.193465",
                    "ticker_sentiment_score": "-0.245996",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.193465",
                    "ticker_sentiment_score": "0.27628",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers - AnaptysBio  ( NASDAQ:ANAB ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37631577/skin-disease-focused-anaptysbio-earns-analyst-upgrade-on-positive-outlook-for-clini",
            "time_published": "20240312T184852",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Monday, AnaptysBio Inc ANAB reported a fourth-quarter 2023 EPS of $ ( 1.59 ) , slightly better than the consensus of $ ( 1.60 ) . The company reported sales of $9.01 million, surpassing the consensus of $2.23 million.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Chem-Lab_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.242434,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ANAB",
                    "relevance_score": "0.682689",
                    "ticker_sentiment_score": "0.405936",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.078327",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37620871/unpacking-the-latest-options-trading-trends-in-eli-lilly-and-co",
            "time_published": "20240312T140118",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 19 unusual trades. Delving into the details, we found 42% of traders were bullish, while 57% showed bearish tendencies.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.002411,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.814341",
                    "ticker_sentiment_score": "-0.028518",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.087824",
                    "ticker_sentiment_score": "-0.10524",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant",
            "url": "https://www.fool.com/investing/2024/03/12/1-big-new-reason-to-buy-novo-nordisk-stock-hand-ov/",
            "time_published": "20240312T114500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The pharma giant could have yet another knockout obesity drug on the way.",
            "banner_image": "https://media.ycharts.com/charts/5c068ae6a3c61bfe2d5aa4e4398ea40e.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.18728,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.089984",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.089984",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.323785",
                    "ticker_sentiment_score": "0.129602",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Meet the Unknown Small-Cap Company That's Been Paying a Dividend for at Least 66 Years Longer Than Coca-Cola, ExxonMobil, and Eli Lilly",
            "url": "https://www.fool.com/investing/2024/03/12/pay-dividend-66-years-longer-coca-cola-exxonmobil/",
            "time_published": "20240312T092100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "A relatively tiny company ($508 million market cap) that most investors have never heard of has been doling out a consecutive dividend for over two centuries -- including 104 years longer than Coca-Cola!",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768822%2Fgetting-paid-dividends-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.171844,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.267926",
                    "ticker_sentiment_score": "0.060302",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "YORW",
                    "relevance_score": "0.169437",
                    "ticker_sentiment_score": "-0.024071",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.299884",
                    "ticker_sentiment_score": "0.088436",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.299884",
                    "ticker_sentiment_score": "0.158856",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic - 'Shame, Blame And The Weight Loss Revolution' - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/24/03/37605412/gary-black-keeping-tabs-on-oprahs-upcoming-tv-special-about-ozempic-shame-blame-and-the-weight-loss",
            "time_published": "20240312T050946",
            "authors": [
                "Ananya Gairola"
            ],
            "summary": "Future Fund co-founder Gary Black on Monday shared information about legendary television mogul Oprah Winfrey's upcoming TV special, where she will discuss her weight loss journey and the role of GLP-1 weight loss drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Oprah-Winfrey_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.08539,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.396574",
                    "ticker_sentiment_score": "-0.088506",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "-0.068821",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Behind the Scenes of Eli Lilly and Co's Latest Options Trends - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37597261/behind-the-scenes-of-eli-lilly-and-cos-latest-options-trends",
            "time_published": "20240311T190111",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 128 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.007185,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.819198",
                    "ticker_sentiment_score": "0.040833",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.088799",
                    "ticker_sentiment_score": "-0.105459",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly",
            "url": "https://www.zacks.com/stock/news/2238727/the-zacks-analyst-blog-highlights-nvidia-constellation-energy-meta-platforms-advanced-micro-devices-and-eli-lilly",
            "time_published": "20240311T141400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly are part of the Zacks top Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995015"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                }
            ],
            "overall_sentiment_score": 0.18251,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.224072",
                    "ticker_sentiment_score": "0.079315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.224072",
                    "ticker_sentiment_score": "0.165376",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.267315",
                    "ticker_sentiment_score": "0.100265",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.224072",
                    "ticker_sentiment_score": "0.108054",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CEG",
                    "relevance_score": "0.224072",
                    "ticker_sentiment_score": "0.15192",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's  ( NVO )  Wegovy Gets FDA Nod to Reduce Heart Risk",
            "url": "https://www.zacks.com/stock/news/2238445/novo-nordisks-nvo-wegovy-gets-fda-nod-to-reduce-heart-risk",
            "time_published": "20240311T105900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.07767,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.225425",
                    "ticker_sentiment_score": "0.229078",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FGEN",
                    "relevance_score": "0.225425",
                    "ticker_sentiment_score": "-0.028692",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.433215",
                    "ticker_sentiment_score": "-0.103756",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACET",
                    "relevance_score": "0.225425",
                    "ticker_sentiment_score": "-0.028666",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly  ( LLY )  Stock Down as FDA Delays Decision on Donanemab",
            "url": "https://www.zacks.com/stock/news/2238437/lilly-lly-stock-down-as-fda-delays-decision-on-donanemab",
            "time_published": "20240311T103400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.050558,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.409742",
                    "ticker_sentiment_score": "0.036375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VNDA",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.035593",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.061315",
                    "ticker_sentiment_score": "0.089066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.260577",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.098991",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study",
            "url": "https://www.prnewswire.com/news-releases/more-than-two-thirds-of-people-with-atopic-dermatitis-and-skin-of-color-experienced-skin-improvement-in-a-first-of-its-kind-lebrikizumab-study-302084690.html",
            "time_published": "20240310T200000",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.175193,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.246582",
                    "ticker_sentiment_score": "0.190911",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.02506",
                    "ticker_sentiment_score": "0.136412",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LBTSF",
                    "relevance_score": "0.02506",
                    "ticker_sentiment_score": "0.0303",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Forget Tesla: I Think This Stock Should Replace It in the \"Magnificent Seven\"",
            "url": "https://www.fool.com/investing/2024/03/10/forget-tesla-i-think-this-stock-should-replace-it/",
            "time_published": "20240310T132900",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Tesla doesn't look very magnificent these days. But there's another stock that does.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768602/scientist-smiling-holding-tablet-computer.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.17247,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.110973",
                    "ticker_sentiment_score": "0.191625",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.469935",
                    "ticker_sentiment_score": "0.031351",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.514619",
                    "ticker_sentiment_score": "0.12536",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Meet the 5 Stocks That Have Contributed Almost All of the S&P 500's 2024 Gains",
            "url": "https://www.fool.com/investing/2024/03/10/5-stocks-contributed-almost-all-market-2024-gains/",
            "time_published": "20240310T100500",
            "authors": [
                "Daniel Foelber"
            ],
            "summary": "These companies have contributed the lion's share of the S&P 500's 7% year-to-date gain.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767902%2Fgettyimages-1473086836-1201x686-332c1f1.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.204433,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.214937",
                    "ticker_sentiment_score": "0.102298",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.214937",
                    "ticker_sentiment_score": "0.102298",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.162073",
                    "ticker_sentiment_score": "0.097419",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.214937",
                    "ticker_sentiment_score": "0.158636",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.054359",
                    "ticker_sentiment_score": "0.013996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.162073",
                    "ticker_sentiment_score": "0.013969",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?",
            "url": "https://www.fool.com/investing/2024/03/10/is-novo-nordisk-a-buy-after-its-new-obesity-candid/",
            "time_published": "20240310T083300",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Encouraging results recently pushed the pharma stock up to new heights.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768402%2Finvestors-evaluating-a-stock-purchase-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.217219,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.113866",
                    "ticker_sentiment_score": "0.112083",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CURN",
                    "relevance_score": "0.057079",
                    "ticker_sentiment_score": "0.130125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.526003",
                    "ticker_sentiment_score": "0.344971",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Best Stocks to Invest $50,000 in Right Now",
            "url": "https://www.fool.com/investing/2024/03/09/the-best-stocks-to-invest-50000-in-right-now/",
            "time_published": "20240309T150000",
            "authors": [
                "Joe Tenebruso"
            ],
            "summary": "These stalwart companies can help you grow your wealth.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768289/investor-gettyimages-694072990.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.414581,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "0.003805",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.34974",
                    "ticker_sentiment_score": "0.548612",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.294446",
                    "ticker_sentiment_score": "0.479203",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Is Eli Lilly the Best Pharmaceutical Stock for You?",
            "url": "https://www.fool.com/investing/2024/03/09/is-eli-lilly-the-best-pharmaceutical-stock-for-you/",
            "time_published": "20240309T100700",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Lilly's recently approved weight-loss drug is off to a good start.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768573%2Fgettyimages-1276837766.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999986"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.271218,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.055364",
                    "ticker_sentiment_score": "0.037895",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.555067",
                    "ticker_sentiment_score": "0.35693",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055364",
                    "ticker_sentiment_score": "0.034028",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Flopped on Friday",
            "url": "https://www.fool.com/investing/2024/03/08/why-eli-lilly-stock-flopped-on-friday/",
            "time_published": "20240309T031608",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "An important new drug's potential approval has been pushed back, and the timing is unclear.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768670/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.100099,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.730535",
                    "ticker_sentiment_score": "0.190361",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies - Or Could They Get Another Lift? - Eli Lilly and Co  ( NYSE:LLY ) , Walt Disney  ( NYSE:DIS ) ",
            "url": "https://www.benzinga.com/general/entertainment/24/03/37570233/oprah-winfrey-to-spotlight-weight-loss-drugs-in-new-tv-special-will-shame-blame-come-to-dru",
            "time_published": "20240308T215905",
            "authors": [
                "Chris Katje"
            ],
            "summary": "Legendary television mogul Oprah Winfrey recently announced she was stepping down from the board of directors of WeightWatchers. The announcement, along with fourth-quarter financial results, sent shares of WeightWatchers parent WW International WW lower last month.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Oprah-Winfrey_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.118269,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.136821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WW",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.127329",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo's Weight-Loss Blockbuster Wins Another Approval",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-cardiovascular-fda/",
            "time_published": "20240308T193100",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Novo Nordisk Stock Slumps Despite Winning Approval For Weight-Loss Drug For Heart Benefit Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-NovoNordisk-02-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                }
            ],
            "overall_sentiment_score": -0.032259,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.625937",
                    "ticker_sentiment_score": "0.109844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "-0.073296",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.625937",
                    "ticker_sentiment_score": "-0.329709",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Ozempic or Tesla? Markets are in no doubt which is hotter | Business",
            "url": "https://www.cnn.com/2024/03/08/business/novo-nordisk-share-price-wegovy/index.html",
            "time_published": "20240308T162300",
            "authors": [
                "Anna Cooban"
            ],
            "summary": "Ozempic or Tesla? Markets are in no doubt which is hotter ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1812475431.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Economy",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.034036,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.198439",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.256179",
                    "ticker_sentiment_score": "-0.003894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNSKF",
                    "relevance_score": "0.052112",
                    "ticker_sentiment_score": "0.068617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.305058",
                    "ticker_sentiment_score": "0.242631",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "S&P 500 Soars to New Highs: 5 Best Stocks YTD",
            "url": "https://www.zacks.com/stock/news/2238098/sp-500-soars-to-new-highs-5-best-stocks-ytd",
            "time_published": "20240308T160500",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980716"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                }
            ],
            "overall_sentiment_score": 0.180612,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.105162",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.216301",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.248851",
                    "ticker_sentiment_score": "0.130328",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.150906",
                    "ticker_sentiment_score": "0.12481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CEG",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.190196",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/news/24/03/37562337/in-depth-analysis-eli-lilly-and-co-versus-competitors-in-pharmaceuticals-industry",
            "time_published": "20240308T160013",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly and Co LLY against its key competitors in the ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.193839,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.551009",
                    "ticker_sentiment_score": "0.289642",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "This is Just the Beginning of Mind Medicine",
            "url": "https://moneymorning.com/2024/03/08/this-is-just-the-beginning-of-mind-medicine/",
            "time_published": "20240308T155933",
            "authors": [
                "Chris Johnson"
            ],
            "summary": "My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, \"Why The Psychedelic Boom Is All but Inevitable\" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.",
            "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2024/03/mnmd.png",
            "source": "Money Morning",
            "category_within_source": "RSS",
            "source_domain": "moneymorning.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.723405"
                }
            ],
            "overall_sentiment_score": 0.193082,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.087663",
                    "ticker_sentiment_score": "0.031875",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.087663",
                    "ticker_sentiment_score": "0.058676",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCORF",
                    "relevance_score": "0.043898",
                    "ticker_sentiment_score": "0.097077",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNMD",
                    "relevance_score": "0.379691",
                    "ticker_sentiment_score": "0.301289",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.087663",
                    "ticker_sentiment_score": "0.058676",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Rally Hits Fresh Highs As Nvidia, Bitcoin Soar: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-hits-fresh-highs-as-nvidia-novo-nordisk-bitcoin-soar-weekly-review/",
            "time_published": "20240308T155800",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "The stock market rally suffered a sharp loss Tuesday but quickly rebounded, with the S&P 500 and Nasdaq composite hitting record highs. The Dow Jones fell modestly, but pared losses. Nvidia ( NVDA ) and chipmakers led the advance, while some software names struggled.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/STock-NYSEstockExchange-05-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.032056,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.073763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TGT",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.161391",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VMW",
                    "relevance_score": "0.020848",
                    "ticker_sentiment_score": "0.095449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GTLB",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.029991",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.062488",
                    "ticker_sentiment_score": "0.105246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "-0.095245",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIVN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.096651",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDB",
                    "relevance_score": "0.062488",
                    "ticker_sentiment_score": "-0.011132",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPS",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.102577",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.073763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BASE",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.061438",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.020848",
                    "ticker_sentiment_score": "0.082144",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BURL",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.164906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SE",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.026943",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.124593",
                    "ticker_sentiment_score": "-0.138354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.01093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.067953",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JWN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.074982",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MARA",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.073763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.165265",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.103957",
                    "ticker_sentiment_score": "-0.108494",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IOT",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "-0.134097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVAV",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.102717",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "-0.114471",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROST",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.164906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ANF",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.102577",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.123255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRVL",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.103521",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.123255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.062488",
                    "ticker_sentiment_score": "-0.031232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:ETH",
                    "relevance_score": "0.020848",
                    "ticker_sentiment_score": "0.067571",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "S&P 500 Soars to New Highs: 5 Best Stocks YTD",
            "url": "https://www.zacks.com/stock/news/2238098/sp-500-soars-to-new-highs-5-best-stocks-ytd",
            "time_published": "20240308T150500",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980716"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                }
            ],
            "overall_sentiment_score": 0.180612,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.105162",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.216301",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.248851",
                    "ticker_sentiment_score": "0.130328",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.150906",
                    "ticker_sentiment_score": "0.12481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CEG",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.190196",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Up on Upbeat Data From New Obesity Pill Study",
            "url": "https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study",
            "time_published": "20240308T150300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.190026,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.256719",
                    "ticker_sentiment_score": "0.151479",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.256719",
                    "ticker_sentiment_score": "0.105076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.155786",
                    "ticker_sentiment_score": "0.01855",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.444487",
                    "ticker_sentiment_score": "0.34082",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Investors Heavily Search Eli Lilly and Company  ( LLY ) : Here is What You Need to Know",
            "url": "https://www.zacks.com/stock/news/2237910/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know",
            "time_published": "20240308T140017",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default6.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": 0.248212,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.525907",
                    "ticker_sentiment_score": "0.178495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "FDA Delays Decision On Eli Lilly's Alzheimer Drug",
            "url": "https://www.investors.com/news/technology/fda-delays-decision-on-eli-lillys-alzheimer-drug/",
            "time_published": "20240308T120800",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "The Food and Drug Administration has delayed a decision on Eli Lilly ( LLY ) Alzheimer's drug donanemab, the company said Friday. Eli Lilly stock edged lower. Biogen ( BIIB ) rose. The FDA now wants to convene an advisory panel for the Lilly drug, but there's no date set yet.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.235291,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.766141",
                    "ticker_sentiment_score": "-0.265067",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.199339",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.614436",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.524949",
                    "ticker_sentiment_score": "-0.317406",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab",
            "url": "https://www.prnewswire.com/news-releases/us-food-and-drug-administration-to-convene-advisory-committee-meeting-to-discuss-the-trailblazer-alz-2-study-of-donanemab-302083661.html",
            "time_published": "20240308T114500",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.135527,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.389552",
                    "ticker_sentiment_score": "0.246912",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.045139",
                    "ticker_sentiment_score": "0.142544",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        }
    ]
}